Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AMAZE 10: NNC0487-0111 in Japanese Participants With Overweight or Obesity
NCT07822061Phase 3Recruiting
- Sponsor
- Novo Nordisk
- Start
- Sep 2026
- Primary completion
- Feb 2029
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in obesity comparing NNC0487-0111 with Placebo (2 arms). Primary endpoint: Relative change in body weight at 84 weeks. Started Sep 2026; status: recruiting.
02
Drugs
amycretin
03
Conditions
obesity
Beyond the preview
Go deeper on NCT07822061.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07822061.